In a  mad dash read through the PDF there are two references to "iBETs might disrupt the interaction between protein E and BRDs :

Early on, page 3 has a section specifically stating the SARS-CoV2 envelope interacts with BRD2 and BRD4 which is what got us in this paper. They do not elaborate on what that means, but hopefully RVX is working away behind the scenes to find out.   So, if Abet is not an active antiviral, (not surprising) potentially having the ability to effect the envelope is still hopeful that our horse isn't out of the race just yet.

Also, see Page 10 Fig. D(iii) that shows RVX-208 along with two others as clinical candidates of iBETs that may effect BRD2 and BRD4 interaction with E.